* Bio Path Holdings Inc is expected to show no change in quarterly revenue when it reports results on November 15 for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Bio Path Holdings Inc is for a loss of $1.02 per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Bio Path Holdings Inc is $20.00, above its last closing price of $0.87.
This summary was machine generated November 13 at 15:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments